摘要
Abstract
Objective To investigate the clinical efficacy of Buqi Pingchang Yuyang Decoction (BPYD) combined with mesalazine in the treatment of ulcerative colitis (UC) and its effect on inflammation factors of patients.Methods Eighty-four patients with UC were included in this study and randomly divided into observation and control groups,with 42 cases in each group.Patients in the control group were orally given mesalazine and those in the observation group were given BPYD in addition to mesalazine.After four weeks treatment,the clinical efficacy,symptom score improvement,serum levels of TNF-α,IL-6 and IL-8,and disease recurrence were compared between two groups.Results The clinical efficacies were 69.0％ and 90.5％ for control and observation groups,respectively,which indicated that the observation group had better results (P＜0.05).The symptoms of abdominal pain,diarrhea and bloody mucopurulent stool were not different between two groups before treatment (P ＞ 0.05).However,the above symptoms were significantly improved after treatment in both groups (P＜0.05).Furthermore,the symptoms in the observation group were improved more than the control group (P＜0.05).The serum inflammation factors were not different before treatment in both groups (P ＞ 0.05).After treatment,the serum levels of TNF-α,IL-6 and IL-8 were significantly lower in observation group than those in the control group (P＜0.05).In a 6-month follow-up,the recurrence rates were 43.8％ (7/16) and 18.2％ (4/22)for the control and observation groups,indicating that the recurrence rate in the control group was much higher than that in the observation group (HR=2.9,P ＜0.05).Conclusion BPYD combined with mesalazine in the treatment of UC can improve the clinical efficacy,reduce the inflammation reaction and decrease the recurrence risk.关键词
溃疡性结肠炎/补气平肠愈疡汤/美沙拉嗪/复发风险Key words
Ulcerative colitis/Buqi Pingchang Yuyang Decoction/mesalazine/recurrence risk分类
医药卫生
